Tolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced CLL and NHL

Drug Category : Array
Conference Category : Array
Lead Author : Nastoupil L, et al.
Published Date : 24/06/2017
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/Nastoupil%20IB%20Triplet%20EHA%2025%20June%202017.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top